Languages
Pages
Legal
Explore all categories to find your favorite topic
This is a repository copy of Time to review the role of surrogate endpoints in health policy: state of the art and the way forward White Rose Research Online URL for this…
Surrogate Endpoints: A Regulatory View Greg Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health Food and Drug Administration FDAâs…
Geneva Branch EFFICACY ENDPOINTS IN ONCOLOGY – IS01 Bruxelles 13-16102013 Angelo Tinazzi Cytel Inc., Wilmington Del. USA Succursale de Meyrin – Geneva – Switzerland…
Wim Van der Elst Acknowledgements The research described in this thesis has received funding from the European Union’s 7th Framework Programme for research, technological
Slide 1Biomarkers and Surrogate Endpoints in Drug Development Technical and Regulatory Considerations Biomarkers and Surrogate Endpoints in Drug Development Technical and…
Regulatory acceptability of clinical surrogate endpoints for accelerated US or conditional EU approval of haematological anti-cancer drugs in the light of the new CHMP anti-cancer…
The gap between biomarkers and surrogate endpoints Oncology Dr. Michael Zühlsdorf Bayer Healthcare AG Institute of Clinical Pharmacology, Pharmacodynamics Laboratories…
A10-05 - Executive Summary 1.1 - Surrogate endpoints in oncologyValidity of surrogate endpoints in oncology1 1 Translation of the executive summary of the rapid report A10-05
1 Gaps Between Biomarkers and Surrogate Endpoints: CNS Hermann Fuder Transatlantic Strategies in Early Drug Development Düsseldorf, 19-21 February 2006 2 Overview • Definitions…
Clinical trial endpoints for use in medical product development Elektra J Papadopoulos, MD, MPH Associate Director for Clinical Outcome Assessments Staff Office of New Drugs…
Slide 1 Outline General endpoint considerations Surrogate endpoints Composite endpoints and recurrent events Safety outcomes (adverse events) Slide 2 Outline Some background…
STATISTICS IN MEDICINE Statist. Med. 17, 2435—2462 (1998) STATISTICAL ISSUES FOR HIV SURROGATE ENDPOINTS: POINT/COUNTERPOINT AN NIAID WORKSHOP JEFFREY M. ALBERT1*, JOHN…
Disease Markers 18 2002 39–40 39 IOS Press Foreword Surrogate endpoints in medicine Sudhir Srivastavaa and John A. Wagnerb aCancer Biomarkers Research Group, Division of…
1© CBG-MEB 2© CBG-MEB Surrogate endpoints for fractures ?? regulatory perspective Dr. Frits Lekkerkerker CHMP alternate member Chairman Medicines Evaluation Board in The…
Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, 26-28 June…
Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, 26-28 June…
University of Groningen Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments?…
Surrogate Endpoints: The Challenges are Greater than they Seem March 7, 2005 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington NIDDK…
Special Issue Paper Received 31 October 2014, Accepted 5 October 2015 Published online 3 November 2015 in Wiley Online Library wileyonlinelibrary.com DOI: 10.1002sim.6776…
Geneva Branch EFFICACY ENDPOINTS IN ONCOLOGY – IS01 Bruxelles 13-16102013 Angelo Tinazzi Cytel Inc Wilmington Del USA Succursale de Meyrin – Geneva – Switzerland angelotinazzi@cytelcom…